Answers are grounded in this paper and cite their sources.
Fibroblast activation protein (FAP)-targeted PET tracers enable high-contrast tumor imaging but suffer from rapid clearance and non-specific uptake in inflammatory lesions. The heptapeptide IF7 binds annexin A1 (ANXA1) on tumor vascular endothelium, a target directly accessible from the bloodstream. To overcome these limitations, we developed a heterobivalent PET probe, NOTA-FAPI-IF7, based on a rationally designed dual-targeting strategy that simultaneously engages FAP in cancer-associated fibroblasts and ANXA1 on tumor vasculature. Radiolabeling with 68Ga achieved a radiochemical yield of 92.3 ± 3.6% (decay-corrected, n = 5) with excellent stability (radiochemical purity >97% at all time points). In vitro assays confirmed dual-target binding (IC50 = 27.9 nM, KD = 3.77 nM). Micro-PET imaging demonstrated rapid tumor visualization as early as 10 min post-injection (6.02 ± 0.07% ID/g), with uptake significantly reduced by blocking with excess unlabeled FAPI, IF7, or NOTA-FAPI-IF7. The probe exhibited favorable hydrophilicity (log P = −1.20) and renal clearance with low hepatobiliary uptake. This bispecific strategy, distinct from monospecific and homomultimeric approaches, offers a promising avenue for precision oncologic PET imaging.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: